Comprehensive Summary
The study investigated the molecular mechanisms underlying frontotemporal lobar degeneration (FTLD) associated with amyotrophic lateral sclerosis (ALS), particularly the characterization of dysregulated alternative polyadenylation (APA) patterns and the development of a deep learning model to predict APA regulation. To achieve this, a single-cell atlas was generated from 103,076 nuclei (23 snRNA-seq samples) from the orbitofrontal cortex of ALS individuals. This was sampled from ALS cases caused by mutations in the C9orf72 gene (C9-ALS), both with and without FTLD, and sporadic ALS cases, where there was no clear genetic cause. Analysis revealed that chaperone-mediated protein folding pathways are upregulated in C9-ALS with FTLD, whereas chromatin remodeling pathways are dysregulated across upper-layer excitatory neurons, inhibitory neurons, oligodendrocytes, and astrocytes. Cell-type-specific metabolic changes occurred in neurons, microglia, and oligodendrocyte precursor cells, as well as mitochondrial dysfunction driven by the widespread dysregulation of ribosomal complexes across populations. Neurons exhibited downregulation of associated RNA binding proteins (RBP) (TARDBP, FUS, ATXN2, SETX, and ANXA11), dysregulation of APA patterns, and lengthening of alternatively spliced transcripts. The study also noted consistent upregulation of STMN2 and NEFL across brain regions. To investigate APA regulation, a deep learning network, APA-Net, was developed and revealed the involvement of RBPs in APA regulation. Overall, this work established the transcriptomic alterations and post-transcriptional regulation across ALS/FTLD subtypes, providing a molecular atlas and predictive model to guide to therapeutic advancements.
Outcomes and Implications
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons in the brain and spinal cord, impairing communication to muscle cells. In addition to motor impairment, ALS impacts breathing, cognition, and language, where about 15% of patients experience frontotemporal dementia. The strengthened understanding of cell-type-specific transcriptomic changes in the frontal cortex offered by this study serves as a resource for furthering ALS therapeutic development. Before clinical implementation, further research must be done to quantify changes in cell type abundance and account for the variability in nucleus recovery and cohort size. Another factor to consider is the influence of premortem clinical factors on gene expression, where prospectively collected tissue may allow for accounting cell-type-specific variability in the orbitofrontal cortex in relation to age.